Stockman Asset Management Has $2,372,000 Position in Astrazeneca PLC (AZN)
Stockman Asset Management boosted its position in shares of Astrazeneca PLC (NYSE:AZN) by 6.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,173 shares of the company’s stock after buying an additional 4,305 shares during the period. Astrazeneca PLC comprises about 1.5% of Stockman Asset Management’s investment portfolio, making the stock its 24th largest position. Stockman Asset Management’s holdings in Astrazeneca PLC were worth $2,372,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Fifth Third Bancorp raised its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Astrazeneca PLC by 2,056.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,982 shares of the company’s stock worth $150,000 after buying an additional 4,751 shares in the last quarter. Yorktown Management & Research Co Inc bought a new stake in shares of Astrazeneca PLC during the third quarter worth $210,000. Beacon Trust Co. bought a new stake in shares of Astrazeneca PLC during the second quarter worth $211,000. Finally, Vontobel Swiss Wealth Advisors AG bought a new stake in shares of Astrazeneca PLC during the second quarter worth $217,000. 13.05% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca PLC (NYSE:AZN) traded up 0.74% on Friday, reaching $28.45. 3,459,513 shares of the company’s stock traded hands. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.04. The stock’s 50 day moving average is $27.22 and its 200 day moving average is $30.39. The firm has a market cap of $71.98 billion, a price-to-earnings ratio of 29.19 and a beta of 0.78.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 10th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a net margin of 10.35% and a return on equity of 31.30%. The firm had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The company’s revenue was down 2.6% on a year-over-year basis. On average, equities research analysts predict that Astrazeneca PLC will post $2.07 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Stockman Asset Management Has $2,372,000 Position in Astrazeneca PLC (AZN)” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this report can be accessed at http://www.dailypolitical.com/2017/01/13/stockman-asset-management-has-2372000-position-in-astrazeneca-plc-azn.html.
AZN has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Tuesday, October 4th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, September 28th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 23rd. Bank of America set a $41.00 price target on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research note on Tuesday, October 4th. Finally, Liberum Capital raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Friday, November 25th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Astrazeneca PLC currently has a consensus rating of “Buy” and an average price target of $37.27.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.